All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Johnson & Johnson, and Syndax, and has been supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
Data from the phase I dose escalation study (NCT00839059) evaluating the safety and efficacy of single-agent continuous high dose lenalidomide in patients with relapsed or refractory (R/R) or older patients with newly diagnosed acute myeloid leukemia (AML) who are not suitable for other treatment options, were reported in Haematologica by researchers from the University of Ulm, Ulm, Germany.
Fourteen patients (median age = 71.5 years, range: 35–83) were enrolled between March 2009 – June 2010. Twelve patients with R/R (n = 8) or newly diagnosed (n = 4) AML were treated with a starting dose of 25 mg lenalidomide per day as a continuous treatment until complete remission (CR) or dose-limiting toxicity (DLT) on day 56. Five patients received 25 mg/day lenalidomide with no DLT. Seven patients received 50 mg/day lenalidomide.
On day 22 (first evaluation response time point), seven patients were evaluable for response. Five patients did not continue treatment on trial due to rapid progressive disease (n = 3) or severe infectious complications (n = 2).
In summary, “high-dose lenalidomide in relapsed or refractory as well as elderly treatment naïve AML is not feasible and has a limited efficacy as monotherapy”.
References